See more : Osisko Mining Inc. (OSK.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Entheon Biomedical Corp. (ENBI.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entheon Biomedical Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- NINGBO LIAN TECH C (300784.SZ) Income Statement Analysis – Financial Results
- Tae Kwang Corporation (023160.KQ) Income Statement Analysis – Financial Results
- Everest Re Group, Ltd. (RE) Income Statement Analysis – Financial Results
- Pekin Life Insurance Company (PKIN) Income Statement Analysis – Financial Results
- Emerald Leasing Finance and Investment Company Limited (EMERALD.BO) Income Statement Analysis – Financial Results
Entheon Biomedical Corp. (ENBI.CN)
About Entheon Biomedical Corp.
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 250.32K | 189.68K | 21.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 2.10K | 12.54K | 2.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 250.32K | 187.58K | 9.13K | -2.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 100.00% | 98.90% | 42.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 1.20M | 1.49M | 442.56K | 129.72K | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 563.14K | 2.53M | 4.93M | 3.63M | 528.84K | 169.53K | 117.50K | 2.50K | 0.00 |
Selling & Marketing | 1.18K | 60.60K | 2.20M | 305.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 564.32K | 2.59M | 7.13M | 3.93M | 528.84K | 169.53K | 117.50K | 2.50K | 8.98K |
Other Expenses | 0.00 | 2.10K | 487.65K | 2.72K | 0.00 | -30.12K | -10.94K | -583.00 | 0.00 |
Operating Expenses | 564.32K | 3.79M | 9.12M | 4.38M | 667.27K | 170.02K | 117.77K | 2.50K | 8.98K |
Cost & Expenses | 564.32K | 3.79M | 9.13M | 4.38M | 667.27K | 170.02K | 117.77K | 2.50K | 8.98K |
Interest Income | 7.32K | 756.00 | 10.41K | 7.36K | 0.00 | 11.56K | 1.25K | 1.22K | 118.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 218.00 | 2.60K | 1.22K | 0.00 |
Depreciation & Amortization | 313.99K | 2.10K | 3.84K | 2.72K | 658.56K | -31.01K | -63.34K | -1.86K | 0.00 |
EBITDA | 13.99K | -3.60M | -8.18M | -1.64M | -8.71K | -229.38K | -181.11K | -2.50K | -8.98K |
EBITDA Ratio | 5.59% | -1,870.65% | -40,723.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -313.99K | -3.55M | -9.31M | -4.37M | -658.56K | -170.02K | -117.77K | -636.00 | -8.98K |
Operating Income Ratio | -125.43% | -1,871.75% | -42,974.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 13.99K | 1.54M | 215.87K | -8.82K | -8.71K | -60.07K | -65.94K | -1.22K | 118.00 |
Income Before Tax | -300.00K | -2.06M | -8.89M | -4.38M | -667.27K | -230.09K | -183.71K | -1.86K | -8.86K |
Income Before Tax Ratio | -119.85% | -1,086.83% | -41,008.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 4.97M | -216.64K | -3.46K | -8.71K | -72.55K | -38.73K | -1.86K | 0.00 |
Net Income | -300.00K | -7.03M | -8.67M | -4.38M | -667.27K | -157.53K | -144.98K | -1.86K | -8.86K |
Net Income Ratio | -119.85% | -3,707.31% | -40,008.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.05 | -0.12 | -0.15 | -1.60 | -0.11 | -0.04 | -0.04 | 0.00 | 0.00 |
EPS Diluted | -0.05 | -0.12 | -0.15 | -1.60 | -0.11 | -0.04 | -0.04 | 0.00 | 0.00 |
Weighted Avg Shares Out | 5.91M | 59.09M | 56.83M | 2.74M | 6.04M | 4.18M | 4.04M | 4.04M | 4.04M |
Weighted Avg Shares Out (Dil) | 5.91M | 59.09M | 56.87M | 2.74M | 6.04M | 4.18M | 4.04M | 4.04M | 4.04M |
Source: https://incomestatements.info
Category: Stock Reports